SuperworthKyntra Bio EPS KYNB
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $45.30
- Latest quarter, Q2 FY26
- $2.96
- Fiscal year 2025
- $45.37
Kyntra Bio's earnings per share was $45.30 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $2.96.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $45.37 | n/a |
| FY2024 | −$11.93 | n/a |
| FY2023 | −$73.25 | n/a |
| FY2022 | −$78.50 | n/a |
| FY2021 | −$78.50 | n/a |
| FY2020 | −$53.25 | n/a |
| FY2019 | −$24.00 | n/a |
| FY2018 | −$25.75 | n/a |
| FY2017 | −$41.75 | n/a |
| FY2016 | −$25.50 | n/a |
| FY2015 | −$38.00 | n/a |
| FY2014 | −$125.75 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.96 | n/a | $45.30 | |
| Q1 FY26 | −$3.76 | −427% | $40.46 | |
| Q4 FY25 | −$3.51 | −179% | $45.37 | |
| Q3 FY25 | $49.61 | n/a | $53.34 | |
| Q2 FY25 | −$1.88 | n/a | −$0.52 | |
| Q1 FY25 | $1.15 | n/a | −$2.53 | |
| Q4 FY24 | $4.46 | n/a | −$11.93 | |
| Q3 FY24 | −$4.25 | n/a | −$30.64 | |
| Q2 FY24 | −$3.89 | n/a | −$42.64 | |
| Q1 FY24 | −$8.25 | n/a | −$61.25 | |
| Q4 FY23 | −$14.25 | n/a | −$73.25 | |
| Q3 FY23 | −$16.25 | n/a | −$76.50 |
Against its peers
Companies in Drug Manufacturers - General nearest Kyntra Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KYNBKyntra Bio | $45.30 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Kyntra Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.